Skip to main content
. 2021 Oct 20;8:754254. doi: 10.3389/fcvm.2021.754254

Figure 4.

Figure 4

RACev transplantation preserved mitral regurgitation (MR) and interstitial fibrosis. (A) Representative mitral regurgitation echocardiographic 2D image. (B) At 4 weeks, mitral regurgitation incidences were higher in the Control and MSCev-treated groups than the RACev group. (C) Mitral regurgitation caused end-systolic volume increase in the control and MSCev-treated groups but not in the RACev group. (D, E) Interstitial fibrosis accumulation was greater in the control group than in the MSCev and RACev groups. (F) Anti-fibrosis miRs were significantly upregulated in RACev vs. MSCev. Furthermore, miR-133a-3p and miR-133b are expressed in RACev but not MSCev (G) Previously defined anti-inflammation related miRs such as miR10a-3p and miR-24-2-5p were expressed only in RACev group (RACev vs. MSCev). (H) Cardiomyogenesis-related miR significantly upregulated in RACev vs. MSCev, and miR-208a-3p and miR499a-5p detected in RACev group but not in MSCev. Scale bar = 100μm *P < 0.05; **P < 0.01; ***P < 0.001 vs. the MSCev group. Statistical significance was determined using 2-way ANOVA (for MR and ESV) or one-way ANNOVA (for interstitial fibrosis) followed by Dunn's or Tukey‘s multiple comparison post-hoc tests. The results are presented as mean ± SEM (n = 8–10 per group).